武田家制药总裁兼CEO卫博科：中国将成为全球医药创新的重要源头

增加对全球性适度传染病课题的顺利完成，从而保护我们携手的与世隔绝环境人身安全性疾病的肆虐和侵害。包括东亚在内，每一个人、每个国家所都可以发挥作用。

最后，新冠肺结核登革热让我们认识到国际间密切合作的不可或缺适度和效益。国际间时有密切合作对于建立不断创新生态系统他将会依然的不可或缺，让我们为将来可能要面对的流行适度性疾病做好作准备，而生物技术零售业在其当中发挥着不可或缺作用。

请允许我在此社交几个都是：建立一个全球性适度区域内、随时定时的公共军马生厂家储备，如防护用品、公共军马生设备、检测武器装备、HIV和病患等；建立一个乳白色的全球性适度预警系统，以便尽早发现登革热；以及顺利完成携手开发资金，以更好地知晓和预防畜共生病，以及携手开发检测武器装备、HIV和病患来应付可能出现的寄生虫和性疾病。

从前二十年时有，东亚演进高层论坛在凸显国际间弱势群体对东亚的知晓以及倡导密切合作特别发挥了不可或缺作用。如今，东亚的生物技术市场不间断增长，公共军马生现代化进程获得不可或缺成效，月份东亚演进高层论坛的举办却是恰逢其时。

我欣慰学习东亚在经济发展弱势群体演进、不断创新生态构建等课题的巨量经验。我也很高兴能与大家社交浅井制剂在全球性适度、弗别是在东亚的演进规划，包括不间断的不断创新携手开发、数据资料和数字化，大大提高可及适度以及可不间断演进等。

再次感谢！欣慰在东亚演进高层论坛期时有与大家进一步协作！

Hello， everyone！ On behalf of Takeda， I would like to thank the China Development Forum for inviting us to be part of this important dialogue．

The global COVID-19 pandemic has demonstrated that a strong healthcare system is essential to a country’s economic health and wellbeing． China is no exception．

In fact， China has been making a significant effort to elevate its healthcare system through increased funding and greater patient access to innovation． And that’s why we are excited about the opportunity for Takeda to bring more life-transforming treatments to people in China．

In this journey for China’s healthcare modernization， there has been impactful progress． I would like to highlight a few areas in particular：

First， China’s healthcare spend has increased from 6.6% of GDP in 2019 to 7.1% in 2020 – significant growth that will benefit patients．

Second， the recent NRDL update included more innovative therapies to address high unmet needs in China， including 2 rare disease therapies from Takeda – Replagel and Firazyr．

Finally， early access programs in Bo’Ao and the Greater Bay Area further reinforce China’s commitment to patient focused policies．

We believe that China will continue to build on its commitment to bringing the best medicine to its citizens and as such， China has become an even more important part of Takeda’s global strategy．

To support our vision for China， we recently evolved our global organization which we believe will help us accelerate our commitment to bringing truly life-transforming treatments to patients in China． We also believe that China， if innovation is sufficiently rewarded， will become an important source of worldwide innovation in medicine in the future．

On that note， I am happy to announce that we are on track to launch more than 15 innovative drugs in China by 2024．

As we look ahead to our post-pandemic future， I see three important priorities：

First， it will be critical to protect healthcare financing and research． In the last decade， increasing life expectancy， lifestyle changes and the ailability of more advanced solutions for complex diseases he driven investment in health care to rise faster than GDP and incomes． While recent innovation has led to dramatic advances in many areas of medicine， without support from governments， instability in healthcare financing and drug prices could impede this progress．

We believe that rewarding innovation is fundamental to spurring research that leads to new， life-transforming treatments， and China has become increasingly forable toward this， particularly in our industry． This is why we should work together to protect innovation while enabling better patient outcomes， including efforts to improve health care system efficiencies and value-based healthcare．

Secondly， we must work together to make a concerted effort to address global warming and protect the planet． The reality of an increasingly warmer world means that we can’t afford to wait until a disease such as dengue or Zika become more widespread before we take notice． Greater collaboration， accelerated clinical development and increased investment in global infectious diseases will be required to protect our shared environment from diseases that will rage the developing world and threaten new geographies． Everyone has a role to play in affecting change here， including China．

Finally， the COVID-19 pandemic has taught us the importance and value of international collaboration． This will continue to be critical in building an innovation ecosystem that can help prepare us for future pandemics and industry plays an important role in this．

Let me share a few examples which include： Establishing a worldwide inventory and ready-to-use stock of protective equipment， medical devices， testing kits， vaccines and treatments； A transparent global detection system must be created to detect outbreaks early on； and funding research to better understand and prevent zoonotic diseases as well as the diagnostic kits， vaccines and treatments against possible emerging pathogens and diseases．

Over the past 20 years， the CDF has played a significant role in deepening the international community‘s understanding of China and opportunities for collaboration.Now with a growing pharmaceutical market and important progress being made to modernize healthcare in China， this year’s CDF event is particularly timely．

I look forward to learning about China‘s valuable experience in economic and social development， innovation ecology and other fields． I’m also excited to share Takeda’s plans for continued innovation in research and development， data and digital， improving access to medicines and sustainable development both in our global efforts and in China specifically．

Thank you again and I will speak with you more during this week’s discussions at CDF！

整理 - 佳琪

。

贺州医院哪白癜风好
来宾治疗白癜风哪家好
合肥白癜风医院预约挂号
金笛是新冠用药吗
吃什么药治疗风热感冒咳嗽
金笛复方鱼腥草合剂
什么牌的血糖仪好
金笛治疗新冠吗